Changes in design of Meril Life Sciences Myval Transcatheter Heart Valve approved by CDSCO panel

Published On 2021-06-23 11:24 GMT   |   Update On 2021-06-23 11:24 GMT
Advertisement

New Delhi: Approving the minor changes proposed by the Meril Life Sciences regarding the design of Myval Transcatheter Heart Valve (THV) and ballon catheter, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has asked Meril Life Sciences, an indigenous global medical devices company, to submit Post Marketing surveillance (PMS) data periodically to CDSCO for review.

Advertisement

Meril Life Sciences introduced the first ever indigenously designed and manufactured Transcatheter Aortic Heart Valve (TAVR) - Myval in 2018. The Myval TAVR technology had received approval for use by Central Drugs Standard Control Organization (CDSCO) on the basis of successful results from a clinical trial done in India.

With the launch, Meril, became the first Indian company to make Transcatheter Aortic Heart Valve Replacement (TAVR) Therapy commercially available on the world stage.

Myval THV is a newer-generation, balloon-expandable TAVR system with features that facilitate accurate positioning of the bioprosthetic valve and favorable procedural and clinical outcomes.

Also Read: Meril Launches Myval- Indigenously Developed TAVR Therapy In India

The recent nod to minor changes in the design of Myval Transcatheter Heart Valve (THV), came in response to the proposal presented by Meril Life Sciences for the same in order to increase the performance of the device.

During the 87th SEC meeting for Cardiovascular & Renal held on 10.06.2021, 11.06.2021 and 14.06.2021 at CDSCO, the expert panel examined the minor changes proposed by the firm in the design of the Myval transcatheter heart valve (model 1 and model 2) and ballon catheter medical device.

After detailed deliberation, the committee recommended for approval of the proposed minor change in Myval transcatheter heart valve (model 1 and model 2) and ballon catheter medical device.

"The firm shall submit PMS data periodically to CDSCO for review," the panel noted.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News